New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:32 EDTADXSAdvaxis announces first patient dosed in Phase 1/2 ADXS-HPV
Advaxis announced that the first patient has been dosed in a Phase 1/2 “window of opportunity” study. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the “window” of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors. This investigator-initiated clinical study is designed to enroll 25 patients with human papillomavirus-positive stage II-IV squamous cell carcinoma of the oropharynx who are scheduled to undergo TORS. The primary objective of this study is to assess the safety, efficacy, and immunogenicity of ADXS-HPV in this patient population prior to undergoing surgery.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ADXS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use